Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn R Webster

Showing results (41-50 of 131) with videos related to

Pageof 14
Sort By:
Pain Medicine (Malden, Mass.)|March 31, 2012
Overdose deaths demand a new paradigm for opioid rotationLynn R Webster, Perry G Fine
Pain Medicine (Malden, Mass.)|September 10, 2013
Benzodiazepines in long-term opioid therapyGary M Reisfield, Lynn R Webster
Pain Medicine (Malden, Mass.)|October 14, 2015
Opioid Therapy and Sleep Disorders: Risks and Mitigation StrategiesMartin D Cheatle, Lynn R Webster
Pain Medicine (Malden, Mass.)|December 13, 2005
Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk ToolLynn R Webster, Rebecca M Webster
Pain Medicine (Malden, Mass.)|September 26, 2008
Pain and addiction interfaceSteven D Passik, Lynn R Webster
American Journal of Therapeutics|July 22, 2006
Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic painLynn R Webster, Mary Jean Walker
Pain Medicine (Malden, Mass.)|February 12, 2009
Unintended harm from opioid prescribing guidelinesScott M Fishman, Lynn R Webster
Pain and Therapy|May 7, 2022
Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled TrialLynn R Webster, Jacqueline Cater, Thomas Smith
Substance Abuse and Rehabilitation|July 2, 2016
Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individualsLynn R Webster, Michael Camilleri, Andrew Finn
Expert Opinion on Investigational Drugs|February 27, 2009
Opioid formulations in development designed to curtail abuse: who is the target?Lynn R Webster, Brad Bath, Robert A Medve
Pageof 14

Showing results (41-50 of 131) with videos related to

Sort By:
Pageof 14
Pain Medicine (Malden, Mass.)|March 31, 2012
Overdose deaths demand a new paradigm for opioid rotationLynn R Webster, Perry G Fine
Pain Medicine (Malden, Mass.)|September 10, 2013
Benzodiazepines in long-term opioid therapyGary M Reisfield, Lynn R Webster
Pain Medicine (Malden, Mass.)|October 14, 2015
Opioid Therapy and Sleep Disorders: Risks and Mitigation StrategiesMartin D Cheatle, Lynn R Webster
Pain Medicine (Malden, Mass.)|December 13, 2005
Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk ToolLynn R Webster, Rebecca M Webster
Pain Medicine (Malden, Mass.)|September 26, 2008
Pain and addiction interfaceSteven D Passik, Lynn R Webster
American Journal of Therapeutics|July 22, 2006
Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic painLynn R Webster, Mary Jean Walker
Pain Medicine (Malden, Mass.)|February 12, 2009
Unintended harm from opioid prescribing guidelinesScott M Fishman, Lynn R Webster
Pain and Therapy|May 7, 2022
Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled TrialLynn R Webster, Jacqueline Cater, Thomas Smith
Substance Abuse and Rehabilitation|July 2, 2016
Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individualsLynn R Webster, Michael Camilleri, Andrew Finn
Expert Opinion on Investigational Drugs|February 27, 2009
Opioid formulations in development designed to curtail abuse: who is the target?Lynn R Webster, Brad Bath, Robert A Medve
Pageof 14